Trials / Withdrawn
WithdrawnNCT04757090
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 89Zr-trastuzumab | -To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of "cold" unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure. |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-02-16
- Last updated
- 2021-12-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04757090. Inclusion in this directory is not an endorsement.